BACKGROUND: Peripheral artery disease (PAD) and its severe form, chronic limb-threatening ischemia (CLTI), significantly impair blood flow to the lower extremities, affecting millions of adults ...

The Ethena-backed eSui Dollar (suiUSDe) has launched on Sui Mainnet, expanding the network’s stablecoin offerings and introducing the network's first synthetic dollar to onchain trading and yield ...

Cracker Barrel is once again at the center of a viral conversation — but this time, it’s not about pancakes or rocking chairs. A leaked internal memo has sparked widespread online debate, claiming ...

Abstract: Heterogeneous devices in edge computing bring challenges as well as opportunities for edge computing to utilize powerful and heterogeneous hardware for a variety of complex tasks. In this ...

Editor’s note: Sreekumar Somasundaram is a senior supply chain technical program manager at AWS. This article and its content was created prior to his current position with AWS. One of the core ...

WASHINGTON — In his first public testimony before Congress about his investigations into President Donald Trump, former special counsel Jack Smith warned Americans not to take the rule of law for ...

Geopolitics and supply chain risk have emerged as top concerns for Chief Legal Officers. These factors are shaping strategic plans and competitive advantage as well as day-to-day operations. Along the ...

Cardano’s long-developing privacy architecture finally took a concrete step this week with the market debut of Midnight’s NIGHT token, which has doubled since launch. NIGHT’s first sessions were ...

REBALANCING TRADE WITH CHINA: This week in the Republic of Korea, President Donald J. Trump reached a trade and economic deal with President Xi Jinping of China—a massive victory that safeguards U.S.

In advance of President Donald Trump’s upcoming visit to South Korea later this month—where he is expected to meet Chinese President Xi Jinping for the first time since 2019—China announced that it ...

The FDA has scrapped a rule that would have allowed the agency to regulate lab-developed tests as medical devices. Under the rule, the FDA would have phased in oversight of laboratory-developed tests ...